XML 37 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholders’ Deficiency (Details) - Schedule of the total equity-based compensation expense related to all of the company’s equity-based awards recognized - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Shareholders’ Deficiency (Details) - Schedule of the total equity-based compensation expense related to all of the company’s equity-based awards recognized [Line Items]    
Total share-based compensation expense $ 2,238 $ 2,257
Research and development [Member]    
Shareholders’ Deficiency (Details) - Schedule of the total equity-based compensation expense related to all of the company’s equity-based awards recognized [Line Items]    
Total share-based compensation expense 1,013 762
Marketing and business development [Member]    
Shareholders’ Deficiency (Details) - Schedule of the total equity-based compensation expense related to all of the company’s equity-based awards recognized [Line Items]    
Total share-based compensation expense 162 58
General and administrative [Member]    
Shareholders’ Deficiency (Details) - Schedule of the total equity-based compensation expense related to all of the company’s equity-based awards recognized [Line Items]    
Total share-based compensation expense $ 1,063 $ 1,437